These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9518409)

  • 1. Patient care after percutaneous coronary artery interventions.
    Rashdan I
    Ann Intern Med; 1998 Apr; 128(7):598; author reply 599-600. PubMed ID: 9518409
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]).
    Daida H; Kuwabara Y; Yokoi H; Nishikawa H; Takatsu F; Nakata Y; Kutsumi Y; Oshima S; Nishiyama S; Ishiwata S; Kato K; Nishimura S; Miyauchi K; Kanoh T; Yamaguchi H
    Am J Cardiol; 2000 Sep; 86(5):550-2, A9. PubMed ID: 11009277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-atherogenic drugs].
    Kanaki T; Saito Y
    Nihon Rinsho; 1998 Oct; 56(10):2635-9. PubMed ID: 9796331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.
    Sirtori CR; Franceschini G
    N Engl J Med; 1997 Dec; 337(26):1918; author reply 1919. PubMed ID: 9417525
    [No Abstract]   [Full Text] [Related]  

  • 5. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.
    O'Keefe JH; Stone GW; McCallister BD; Maddex C; Ligon R; Kacich RL; Kahn J; Cavero PG; Hartzler GO; McCallister BD
    Am J Cardiol; 1996 Mar; 77(8):649-52. PubMed ID: 8610621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
    Titov VN; Zaĭtseva TM
    Klin Lab Diagn; 2000 Aug; (8):3-9. PubMed ID: 11031423
    [No Abstract]   [Full Text] [Related]  

  • 7. Vessel size, antioxidants, and restenosis: never too small, not too little, but often too late.
    Edelman ER
    Circulation; 1998 Feb; 97(5):416-20. PubMed ID: 9490233
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
    Lee YJ; Daida H; Yokoi H; Miyano H; Takaya J; Sakurai H; Mokuno H; Yamaguchi H
    Jpn Heart J; 1996 May; 37(3):327-32. PubMed ID: 8774625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probucol: can we step forward in atherosclerosis prevention with an old drug?
    Kajinami K; Akao H
    Atherosclerosis; 2012 Mar; 221(1):34-5. PubMed ID: 22186351
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reduction in the rates of restenosis after coronary angioplasty with simvastatin and probucol].
    Merchán Herrera A; López Mínguez JR; Alonso Ruiz F; Escola JM; Címbora Ortega A; Poblador Curto MA; Redondo Méndez A; Romero Santisteban R; Geniz Gallardo I; González Fernández R; Millán Núñez V
    Rev Esp Cardiol; 1999 Oct; 52(10):778-84. PubMed ID: 10563153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.
    Tardif JC; Côté G; Lespérance J; Gosselin G; Joyal M; de Guise P; Bilodeau L; Doucet S; Harel F; Couturier A; Gallo R; Grégoire J
    Can J Cardiol; 2001 Jan; 17(1):49-55. PubMed ID: 11173314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.
    Tardif JC; Cöté G; Lespérance J; Bourassa M; Lambert J; Doucet S; Bilodeau L; Nattel S; de Guise P
    N Engl J Med; 1997 Aug; 337(6):365-72. PubMed ID: 9241125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis.
    Liu J; Li M; Lu H; Qiao W; Xi D; Luo T; Xiong H; Guo Z
    PLoS One; 2015; 10(4):e0124021. PubMed ID: 25898372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
    Cohen DJ; Carrozza JP; Baim DS
    N Engl J Med; 1999 Dec; 341(24):1853-4; author reply 1854-5. PubMed ID: 10610464
    [No Abstract]   [Full Text] [Related]  

  • 15. Can an old drug prevent restenosis after PTCA?
    Harv Heart Lett; 1998 Apr; 8(8):4-6. PubMed ID: 9549435
    [No Abstract]   [Full Text] [Related]  

  • 16. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.
    Kasai T; Miyauchi K; Kubota N; Kajimoto K; Amano A; Daida H
    Atherosclerosis; 2012 Feb; 220(2):463-9. PubMed ID: 22024277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revascularization of coronary atherosclerosis in patients with diabetes mellitus--there is more to it than meets the image intensifier.
    Petersen JL; Harrington RA
    Am Heart J; 2005 Feb; 149(2):190-3. PubMed ID: 15846254
    [No Abstract]   [Full Text] [Related]  

  • 18. Restenosis revisited--new targets, new therapies.
    Libby P; Ganz P
    N Engl J Med; 1997 Aug; 337(6):418-9. PubMed ID: 9241132
    [No Abstract]   [Full Text] [Related]  

  • 19. [New strategies in the treatment of restenosis].
    von Hodenberg E; Tost B; Scheffold T
    Z Kardiol; 2000; 89 Suppl 7():19-22. PubMed ID: 11098555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.
    Jay SJ
    N Engl J Med; 1997 Dec; 337(26):1918-9; author reply 1919. PubMed ID: 9417526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.